1. Pink Sheet
  2. >>Archive

Salix Expects Acquisition Of Oceana, Two Products, To Be Quickly Accretive

Although privately held Oceana’s two products – Solesta and Deflux – are regulated by FDA as Class III medical devices, Salix intends to market them with existing sales forces.

Gastroenterology-focused Salix Pharmaceuticals Ltd. will expand its product portfolio and increase its revenues almost immediately with the planned $300 million acquisition of privately held Oceana Therapeutics Inc. Announced during Salix’s third-quarter earnings call Nov. 8, the acquisition would bring the specialty pharma two marketed products – Solesta for fecal incontinence and Deflux for vesicoureteral reflux.

During the call, Salix President and CEO Carolyn Logan said the deal, expected to close in December, “demonstrates our commitment to fulfilling our mission of continuing to be the leading U.S

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet

Brazil To Upgrade Pricing Framework To Keep Up With Market Developments

 
• By Francesca Bruce

Brazil plans to clarify its medicine pricing framework, for example by outlining the procedures for setting medicine prices and bring it up to date with recent developments in the sector.

England: HTA Sandbox Helping To Assess ‘Challenging’ Drugs And Indications

 
• By Eliza Slawther

England’s health technology assessment institute explains how its sandbox environment is helping to test new evaluation methods for drugs or indications with which it does not have experience, such as metabolic dysfunction-associated steatohepatitis.

Unlocking Opportunities: How To Engage With The EMA On Animal Testing Alternatives

 
• By Neena Brizmohun

The European Medicines Agency, like its counterpart in the US, is increasingly focusing on the use of alternatives to animal testing.